Dianthus Therapeutics, Inc.
DNTH
$115.96
$6.365.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 761.00K | 463.00K | 284.00K | 396.00K | 193.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 761.00K | 463.00K | 284.00K | 396.00K | 193.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 761.00K | 463.00K | 284.00K | 396.00K | 193.00K |
| SG&A Expenses | 13.56M | 12.47M | 9.91M | 8.20M | 8.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.24M | 47.00M | 69.83M | 40.68M | 35.12M |
| Operating Income | -61.48M | -46.53M | -69.54M | -40.29M | -34.93M |
| Income Before Tax | -50.22M | -40.83M | -64.43M | -36.77M | -31.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.22M | -40.83M | -64.43M | -36.77M | -31.63M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.22M | -40.83M | -64.43M | -36.77M | -31.63M |
| EBIT | -61.48M | -46.53M | -69.54M | -40.29M | -34.93M |
| EBITDA | -61.45M | -46.50M | -69.51M | -40.26M | -34.90M |
| EPS Basic | -0.90 | -0.85 | -1.43 | -0.97 | -0.88 |
| Normalized Basic EPS | -0.62 | -0.54 | -0.91 | -0.65 | -0.57 |
| EPS Diluted | -0.90 | -0.85 | -1.43 | -0.97 | -0.88 |
| Normalized Diluted EPS | -0.62 | -0.54 | -0.91 | -0.65 | -0.57 |
| Average Basic Shares Outstanding | 56.03M | 48.03M | 44.97M | 37.79M | 35.82M |
| Average Diluted Shares Outstanding | 56.03M | 48.03M | 44.97M | 37.79M | 35.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |